{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:57:43Z","timestamp":1793235463864,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11864-025-01329-1","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:01:25Z","timestamp":1748059285000},"page":"605-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Unmasking the Rare but Lethal Cardiac Complications of Immune Checkpoint Inhibitor Therapy: A Review of Mechanisms, Risk Factors, and Management Strategies"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-7841","authenticated-orcid":false,"given":"Laudy","family":"Chehade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2894-4524","authenticated-orcid":false,"given":"Noura","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9828-6960","authenticated-orcid":false,"given":"Kristel","family":"Dagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-1309","authenticated-orcid":false,"given":"Mohamad","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghid","family":"Amhez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-8466","authenticated-orcid":false,"given":"Mohamad B.","family":"Moumneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7579-2087","authenticated-orcid":false,"given":"Lara","family":"Kreidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-5154","authenticated-orcid":false,"given":"Firas","family":"Kreidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Manuel","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-8403","authenticated-orcid":false,"given":"Ali","family":"Shamseddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"issue":"26","key":"1329_CR1","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"1329_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717\u201326.","journal-title":"Lancet Oncol"},{"issue":"36","key":"1329_CR3","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","volume":"35","author":"JS Frenel","year":"2017","unstructured":"Frenel JS, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035\u201341.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1329_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, et al. Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1329_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, et al. Phase II open-label study of Pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1329_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"1329_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1329_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","volume":"23","author":"RP Patel","year":"2021","unstructured":"Patel RP, et al. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep. 2021;23(7):79.","journal-title":"Curr Oncol Rep"},{"issue":"29","key":"1329_CR9","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.22.00369","volume":"40","author":"AR Naqash","year":"2022","unstructured":"Naqash AR, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the national cancer institute-cancer therapy evaluation program. J Clin Oncol. 2022;40(29):3439\u201352.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1329_CR10","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1329_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.22.01603","volume":"41","author":"P Palassin","year":"2023","unstructured":"Palassin P, et al. Underreporting of major cardiac adverse events with immune checkpoint inhibitors in clinical trials: importance of postmarketing pharmacovigilance surveys. J Clin Oncol. 2023;41(5):1154\u20136.","journal-title":"J Clin Oncol"},{"key":"1329_CR12","doi-asserted-by":"publisher","first-page":"969942","DOI":"10.3389\/fcvm.2022.969942","volume":"9","author":"S Wu","year":"2022","unstructured":"Wu S, et al. Cardiovascular adverse events induced by immune checkpoint inhibitors: a real world study from 2018 to 2022. Front Cardiovasc Med. 2022;9:969942.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"1329_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/cancers14051145","volume":"14","author":"C Li","year":"2022","unstructured":"Li C, Bhatti SA, Ying J. Immune checkpoint inhibitors-associated cardiotoxicity. Cancers. 2022;14(5):1145.","journal-title":"Cancers."},{"key":"1329_CR14","doi-asserted-by":"publisher","first-page":"112516","DOI":"10.1016\/j.biopha.2021.112516","volume":"146","author":"H Alemohammad","year":"2022","unstructured":"Alemohammad H, et al. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomed Pharmacother. 2022;146:112516.","journal-title":"Biomed Pharmacother"},{"key":"1329_CR15","doi-asserted-by":"publisher","first-page":"651634","DOI":"10.3389\/fimmu.2021.651634","volume":"12","author":"M Khan","year":"2021","unstructured":"Khan M, Arooj S, Wang H. Soluble B7-CD28 family inhibitory immune checkpoint proteins and anti-cancer immunotherapy. Front Immunol. 2021;12:651634.","journal-title":"Front Immunol"},{"key":"1329_CR16","doi-asserted-by":"publisher","first-page":"103031","DOI":"10.1016\/j.critrevonc.2020.103031","volume":"153","author":"M Alizadeh","year":"2020","unstructured":"Alizadeh M, et al. The potentials of immune checkpoints for the treatment of blood malignancies. Crit Rev Oncol Hematol. 2020;153:103031.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1329_CR17","doi-asserted-by":"publisher","first-page":"106700","DOI":"10.1016\/j.intimp.2020.106700","volume":"86","author":"S Tang","year":"2020","unstructured":"Tang S, et al. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86:106700.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1329_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1329_CR19","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1329_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","volume":"46","author":"E Raschi","year":"2023","unstructured":"Raschi E, et al. Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians. Drug Saf. 2023;46(9):819\u201333.","journal-title":"Drug Saf"},{"issue":"4","key":"1329_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/vaccines10040540","volume":"10","author":"D Ronen","year":"2022","unstructured":"Ronen D, et al. Exploring the mechanisms underlying the cardiotoxic effects of immune checkpoint inhibitor therapies. Vaccines. 2022;10(4):540.","journal-title":"Vaccines."},{"issue":"12","key":"1329_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"10","key":"1329_CR23","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante N, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23(10):1739\u201347.","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 7","key":"1329_CR24","doi-asserted-by":"publisher","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","volume":"58","author":"SC Weinmann","year":"2019","unstructured":"Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology. 2019;58(Suppl 7):vii59\u201367.","journal-title":"Rheumatology."},{"issue":"11","key":"1329_CR25","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik AH, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128(11):1780\u2013801.","journal-title":"Circ Res"},{"issue":"18","key":"1329_CR26","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"7","key":"1329_CR27","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.3324\/haematol.2017.185777","volume":"103","author":"N Martinez-Calle","year":"2018","unstructured":"Martinez-Calle N, et al. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica. 2018;103(7):e318\u201321.","journal-title":"Haematologica"},{"issue":"5238","key":"1329_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse P, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985\u20138.","journal-title":"Science"},{"issue":"3","key":"1329_CR29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4049\/jimmunol.0903369","volume":"185","author":"H Ying","year":"2010","unstructured":"Ying H, et al. Cutting edge: CTLA-4\u2013B7 interaction suppresses Th17 cell differentiation. J Immunol. 2010;185(3):1375\u20138.","journal-title":"J Immunol"},{"issue":"5","key":"1329_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541\u20137.","journal-title":"Immunity"},{"key":"1329_CR31","first-page":"100374","volume":"40","author":"F Kreidieh","year":"2024","unstructured":"Kreidieh F, McQuade J. Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: beyond ischemia with non-obstructive coronary arteries (INOCA). Am Heart J Plus. 2024;40:100374.","journal-title":"Am Heart J Plus"},{"issue":"12","key":"1329_CR32","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","volume":"29","author":"C Fenioux","year":"2023","unstructured":"Fenioux C, et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med. 2023;29(12):3100\u201310.","journal-title":"Nat Med"},{"issue":"5","key":"1329_CR33","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, et al. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100\u201315.","journal-title":"Cancer Discov"},{"issue":"7","key":"1329_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41571-023-00762-1","volume":"20","author":"DB Johnson","year":"2023","unstructured":"Johnson DB, Menzies AM. Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis. Nat Rev Clin Oncol. 2023;20(7):427\u20138.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1329_CR35","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.amjcard.2019.01.013","volume":"123","author":"N Palaskas","year":"2019","unstructured":"Palaskas N, et al. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol. 2019;123(8):1351\u20137.","journal-title":"Am J Cardiol"},{"issue":"24","key":"1329_CR36","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299\u2013311.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"1329_CR37","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","volume":"6","author":"YB Hu","year":"2017","unstructured":"Hu YB, et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017;6(Suppl 1):S8-s20.","journal-title":"Transl Lung Cancer Res"},{"issue":"22","key":"1329_CR38","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1111\/bph.13802","volume":"174","author":"AC Foks","year":"2017","unstructured":"Foks AC, Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br J Pharmacol. 2017;174(22):3940\u201355.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"1329_CR39","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1161\/CIRCRESAHA.124.324260","volume":"135","author":"L Lou","year":"2024","unstructured":"Lou L, et al. Visualizing immune checkpoint inhibitors derived inflammation in atherosclerosis. Circ Res. 2024;135(10):990\u20131003.","journal-title":"Circ Res"},{"key":"1329_CR40","doi-asserted-by":"publisher","first-page":"107148","DOI":"10.1016\/j.carpath.2019.107148","volume":"43","author":"JL Newman","year":"2019","unstructured":"Newman JL, Stone JR. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis. Cardiovasc Pathol. 2019;43:107148.","journal-title":"Cardiovasc Pathol"},{"key":"1329_CR41","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.5114\/amsad.2017.72531","volume":"2","author":"R Nykl","year":"2017","unstructured":"Nykl R, et al. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis. 2017;2:e100\u20132.","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"11","key":"1329_CR42","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1161\/HYPERTENSIONAHA.122.19865","volume":"79","author":"S Minegishi","year":"2022","unstructured":"Minegishi S, et al. Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: a systematic literature review and meta-analysis. Hypertension. 2022;79(11):2611\u201321.","journal-title":"Hypertension"},{"issue":"3","key":"1329_CR43","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1161\/HYPERTENSIONAHA.122.20407","volume":"80","author":"I Turker","year":"2023","unstructured":"Turker I, et al. Combination immune checkpoint inhibitor therapy is associated with increased blood pressure in melanoma patients. Hypertension. 2023;80(3):e43\u20135.","journal-title":"Hypertension"},{"issue":"1","key":"1329_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000261","volume":"8","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020;8(1): e000261.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1329_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","volume":"180","author":"TG Gergely","year":"2023","unstructured":"Gergely TG, et al. Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. Br J Pharmacol. 2023;180(6):740\u201361.","journal-title":"Br J Pharmacol"},{"issue":"21","key":"1329_CR46","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085\u20137.","journal-title":"Circulation"},{"issue":"6","key":"1329_CR47","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/jcmm.12467","volume":"19","author":"L Liu","year":"2015","unstructured":"Liu L, et al. PD-1\/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation. J Cell Mol Med. 2015;19(6):1223\u201333.","journal-title":"J Cell Mol Med"},{"key":"1329_CR48","doi-asserted-by":"publisher","first-page":"1104888","DOI":"10.3389\/fonc.2023.1104888","volume":"13","author":"L Luo","year":"2023","unstructured":"Luo L, et al. Risk factors for cardiovascular adverse events from immune checkpoint inhibitors. Front Oncol. 2023;13:1104888.","journal-title":"Front Oncol"},{"issue":"9","key":"1329_CR49","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447\u201358.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1329_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1684\/ejd.2021.4009","volume":"31","author":"C Scard","year":"2021","unstructured":"Scard C, et al. Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels. Eur J Dermatol. 2021;31(2):205\u201312.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"1329_CR51","first-page":"3","volume":"8","author":"ZL Brumberger","year":"2022","unstructured":"Brumberger ZL, et al. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardiooncology. 2022;8(1):3.","journal-title":"Cardiooncology"},{"issue":"11","key":"1329_CR52","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.3390\/cancers12113480","volume":"12","author":"R Noseda","year":"2020","unstructured":"Noseda R, et al. Pre-existing cardiovascular conditions as clinical predictors of myocarditis reporting with immune checkpoint inhibitors: a vigibase study. Cancers. 2020;12(11):3480.","journal-title":"Cancers."},{"key":"1329_CR53","doi-asserted-by":"publisher","first-page":"882167","DOI":"10.3389\/fcvm.2022.882167","volume":"9","author":"X Chen","year":"2022","unstructured":"Chen X, et al. Immune checkpoint inhibitor-associated cardiotoxicity in solid tumors: real-world incidence, risk factors, and prognostic analysis. Front Cardiovasc Med. 2022;9:882167.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"1329_CR54","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1329_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cpcardiol.2012.07.003","volume":"38","author":"D Fairweather","year":"2013","unstructured":"Fairweather D, Cooper LT Jr, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38(1):7\u201346.","journal-title":"Curr Probl Cardiol"},{"issue":"11","key":"1329_CR56","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","volume":"5","author":"Y Zamami","year":"2019","unstructured":"Zamami Y, et al. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncol. 2019;5(11):1635\u20137.","journal-title":"JAMA Oncol"},{"issue":"669","key":"1329_CR57","doi-asserted-by":"publisher","first-page":"eabo1981","DOI":"10.1126\/scitranslmed.abo1981","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022;14(669):eabo1981.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1329_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s40001-023-01464-1","volume":"28","author":"FYN Lessomo","year":"2023","unstructured":"Lessomo FYN, et al. A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. Eur J Med Res. 2023;28(1):495.","journal-title":"Eur J Med Res"},{"issue":"8","key":"1329_CR59","doi-asserted-by":"publisher","first-page":"791","DOI":"10.4330\/wjc.v6.i8.791","volume":"6","author":"KB Wagner","year":"2014","unstructured":"Wagner KB, Felix SB, Riad A. Innate immune receptors in heart failure: Side effect or potential therapeutic target? World J Cardiol. 2014;6(8):791\u2013801.","journal-title":"World J Cardiol"},{"issue":"1","key":"1329_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.34172\/jcvtr.2020.07","volume":"12","author":"A Khorrami","year":"2020","unstructured":"Khorrami A, et al. Oxidized cholesterol exacerbates toll-like receptor 4 expression and activity in the hearts of rats with myocardial infarction. J Cardiovasc Thorac Res. 2020;12(1):43\u201350.","journal-title":"J Cardiovasc Thorac Res"},{"key":"1329_CR61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.05.004","volume":"45","author":"AH Lichtman","year":"2013","unstructured":"Lichtman AH. The heart of the matter: Protection of the myocardium from T cells. J Autoimmun. 2013;45:90\u20136.","journal-title":"J Autoimmun"},{"issue":"10","key":"1329_CR62","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188(10):4876\u201384.","journal-title":"J Immunol"},{"key":"1329_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.yjmcc.2022.03.010","volume":"167","author":"Y Kim","year":"2022","unstructured":"Kim Y, Seidman JG, Seidman CE. Genetics of cancer therapy-associated cardiotoxicity. J Mol Cell Cardiol. 2022;167:85\u201391.","journal-title":"J Mol Cell Cardiol"},{"issue":"14","key":"1329_CR64","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"8","key":"1329_CR65","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474\u2013502.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"1329_CR66","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.1002\/cam4.5438","volume":"12","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Arrhythmic events associated with immune checkpoint inhibitors therapy: a real-world study based on the food and drug administration adverse event reporting system database. Cancer Med. 2023;12(6):6637\u201348.","journal-title":"Cancer Med"},{"issue":"5","key":"1329_CR67","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.esmoop.2021.100252","volume":"6","author":"P Jain","year":"2021","unstructured":"Jain P, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open. 2021;6(5):100252.","journal-title":"ESMO Open"},{"issue":"23","key":"1329_CR68","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139.","journal-title":"N Engl J Med"},{"issue":"10122","key":"1329_CR69","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748\u201357.","journal-title":"Lancet"},{"issue":"24","key":"1329_CR70","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"2","key":"1329_CR71","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares LG, et al. First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations. J Thorac Oncol. 2023;18(2):204\u201322.","journal-title":"J Thorac Oncol"},{"issue":"7890","key":"1329_CR72","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature"},{"issue":"9","key":"1329_CR73","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"issue":"41","key":"1329_CR74","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"8","key":"1329_CR75","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983\u201393.","journal-title":"Ann Oncol"},{"issue":"5","key":"1329_CR76","doi-asserted-by":"publisher","first-page":"e218065","DOI":"10.1001\/jamanetworkopen.2021.8065","volume":"4","author":"R Pei","year":"2021","unstructured":"Pei R, et al. Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta-analysis and cost-effectiveness analysis. JAMA Netw Open. 2021;4(5):e218065.","journal-title":"JAMA Netw Open"},{"issue":"10212","key":"1329_CR77","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328.","journal-title":"Lancet"},{"issue":"21","key":"1329_CR78","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp KL, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J Clin Oncol. 2022;40(21):2295\u2013306.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1329_CR79","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"6","key":"1329_CR80","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Br\u00f6ckelmann","year":"2020","unstructured":"Br\u00f6ckelmann PJ, et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial. JAMA Oncol. 2020;6(6):872\u201380.","journal-title":"JAMA Oncol"},{"key":"1329_CR81","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, et al. Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36\u201349.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1329_CR82","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/biology12030472","volume":"12","author":"D Wang","year":"2023","unstructured":"Wang D, Bauersachs J, Berliner D. Immune checkpoint inhibitor associated myocarditis and cardiomyopathy: a translational review. Biology. 2023;12(3):472.","journal-title":"Biology"},{"key":"1329_CR83","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine. 2024;70:102536.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1329_CR84","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"key":"1329_CR85","doi-asserted-by":"publisher","first-page":"1309100","DOI":"10.3389\/fcvm.2024.1309100","volume":"11","author":"A Inno","year":"2024","unstructured":"Inno A, et al. Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis. Front Cardiovasc Med. 2024;11:1309100.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"1329_CR86","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol."},{"issue":"8","key":"1329_CR87","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995\u20131008.","journal-title":"Lancet Oncol"},{"issue":"16","key":"1329_CR88","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.22.02152","volume":"41","author":"V Makker","year":"2023","unstructured":"Makker V, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775. J Clin Oncol. 2023;41(16):2904\u201310.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1329_CR89","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1329_CR90","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","volume":"22","author":"AG Sacco","year":"2021","unstructured":"Sacco AG, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883\u201392.","journal-title":"Lancet Oncol"},{"issue":"10240","key":"1329_CR91","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835\u201344.","journal-title":"Lancet"},{"key":"1329_CR92","doi-asserted-by":"publisher","unstructured":"Niimura T, et al. Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination. Front Drug Safet Regul. 2023;3. https:\/\/doi.org\/10.3389\/fdsfr.2023.1213771","DOI":"10.3389\/fdsfr.2023.1213771"},{"issue":"4","key":"1329_CR93","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","volume":"13","author":"S Du","year":"2018","unstructured":"Du S, et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol. 2018;13(4):510\u201320.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1329_CR94","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/1759-7714.13250","volume":"11","author":"X Guo","year":"2020","unstructured":"Guo X, et al. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. Thorac Cancer. 2020;11(2):475\u201380.","journal-title":"Thorac Cancer"},{"issue":"5","key":"1329_CR95","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ijrobp.2017.06.2452","volume":"99","author":"CJ Myers","year":"2017","unstructured":"Myers CJ, Lu B. Decreased survival after combining thoracic irradiation and an Anti-PD-1 antibody correlated with increased T-cell infiltration into cardiac and lung tissues. Int J Radiat Oncol Biol Phys. 2017;99(5):1129\u201336.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1329_CR96","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","volume":"8","author":"MS Anscher","year":"2022","unstructured":"Anscher MS, et al. Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and drug administration database. JAMA Oncol. 2022;8(2):232\u201340.","journal-title":"JAMA Oncol"},{"key":"1329_CR97","doi-asserted-by":"publisher","first-page":"1025455","DOI":"10.3389\/fonc.2022.1025455","volume":"12","author":"C Son","year":"2023","unstructured":"Son C, et al. Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy. Front Oncol. 2023;12:1025455.","journal-title":"Front Oncol"},{"key":"1329_CR98","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","volume":"151","author":"CM Sha","year":"2020","unstructured":"Sha CM, et al. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. Radiother Oncol. 2020;151:141\u20138.","journal-title":"Radiother Oncol"},{"issue":"11","key":"1329_CR99","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360.","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"1329_CR100","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1329_CR101","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(4):387\u2013405.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"1329_CR102","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"1329_CR103","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","volume":"74","author":"S Ball","year":"2019","unstructured":"Ball S, et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. J Am Coll Cardiol. 2019;74(13):1714\u201327.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1329_CR104","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/cancers15030986","volume":"15","author":"G S\u0142awi\u0144ski","year":"2023","unstructured":"S\u0142awi\u0144ski G, et al. Global longitudinal strain in cardio-oncology: a review. Cancers. 2023;15(3):986.","journal-title":"Cancers."},{"key":"1329_CR105","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","volume":"10","author":"YW Zhou","year":"2019","unstructured":"Zhou YW, et al. Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism. Diagnosis and Management Front Pharmacol. 2019;10:1350.","journal-title":"Diagnosis and Management Front Pharmacol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01329-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:06:00Z","timestamp":1757178360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01329-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":105,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01329-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"29 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}